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F
or half a century, natural 
products from microorganisms 
have been the main source 
of medicines for treating infectious 
disease. The most important chemical 
class of these antibiotics, apart from 
the penicillins, is the polyketides. They 
are made by the stepwise building of 
long carbon chains, two atoms at a 
time, by multifunctional enzymes that 
determine the chain length, oxidation 
state, and pattern of branching, 
cyclisation, and stereochemistry of the 
molecules in a combinatorial fashion 
to produce an enormous variety of 
structures. Recent elucidation of 
the genetic ‘programming’ of the 
enzymes has opened a new ﬁ  eld of 
drug discovery based on rationally 
engineering the enzymes to produce 
‘unnatural natural products’ with novel 
properties. 
Following the development 
of penicillin for the treatment 
of septicemia in the early 1940s, 
numerous antibiotics were discovered 
and introduced into medicine. While a 
fungus makes penicillin, semisynthetic 
derivatives of which have been a 
mainstay of antibacterial therapy for 
decades, most natural antibacterial 
antibiotics come from a group of soil-
dwelling, ﬁ  lamentous bacteria called 
the actinomycetes, of which Streptomyces 
is the best-known genus. These 
organisms make an amazing array of 
so-called secondary metabolites that 
have evolved to give their producers a 
competitive advantage in the complex 
soil environment, where they are 
exposed to stresses of all kinds (Challis 
and Hopwood 2003). The compounds 
have many functions, but those 
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with antibiotic activity are the most 
important from the human perspective. 
Actinomycete antibiotics include such 
antibacterial compounds as tetracycline 
and erythromycin, antifungal agents 
like candicidin and amphotericin, 
anticancer drugs such as doxorubicin, 
and the antiparasitic avermectin (Walsh 
2003). 
While many different chemical 
classes are represented amongst 
actinomycete antibiotics, one class 
accounts for an extraordinary 
proportion of the important 
compounds, including all those 
mentioned above. This chemical family 
is made up of the polyketides. They 
are synthesized by multifunctional 
enzymes called polyketide synthases 
(PKSs), which are related to the fatty 
acid synthases that make the lipids 
essential for the integrity of cell 
membranes, but they carry out much 
more complex biosynthetic routines. 
Repeated rounds of carbon chain 
building and modiﬁ  cation use a series 
of independently variable reactions 
selected according to a ‘program’ 
characteristic of each PKS (Reeves 
2003). Recent research has focused 
on determining this program so as to 
be able to modify it in rational ways by 
genetic engineering and thus generate 
novel drug candidates. The resulting 
ﬁ  eld of ‘combinatorial biosynthesis’ 
of ‘unnatural natural products’ has 
been given added urgency by the rise 
of multidrug-resistant pathogens, of 
which MRSA (methicillin-resistant 
Staphylococcus aureus) is simply the most 
discussed of a series of threats (Walsh 
2003). How do PKSs work and how can 
we make new ones?
Molecular Diversity
The heart of PKS function is the 
synthesis of long chains of carbon 
atoms by joining (condensing) 
together small organic acids, such as 
acetic and malonic acid, by a so-called 
ketosynthase function. This uses the 
building units in the form of activated 
derivatives, called coenzyme A (CoA) 
esters, so we speak of acetyl-CoA and 
malonyl-CoA, for example. The special 
form of condensation that joins them 
is driven by loss of carbon dioxide. 
Thus, when acetyl-CoA, with two 
carbon atoms, joins with malonyl-CoA, 
with three carbons, one of the latter is 
lost and a chain of four carbon atoms 
results (Figure 1A). Further rounds 
of condensation extend the chain 
by two carbons at each step. If the 
chain-extender unit, instead of being 
malonyl-CoA, is methylmalonyl-CoA, 
which has four carbon atoms, the linear 
carbon chain is still extended by two 
carbons, and the ‘extra’ carbon forms 
a methyl side branch. More complex 
extender units produce more complex 
side branches. 
Choices of the number and type 
of the building units are variables in 
determining polyketide structure. 
Another concerns the keto groups 
(C=O) that appear at every alternate 
carbon atom in the growing chain as 
a result of the condensation process 
(accounting for the name polyketide). 
They may remain intact. Alternatively, 
some may be modiﬁ  ed or removed 
by a series of three steps (Figure 1B), 
any of which may be omitted. This 
results in keto groups remaining at 
some points in the chain; hydroxyl 
DOI: 10.1371/journal.pbio.0020035.g001
Figure 1. The Chemistry of Polyketide Chain Assembly 
(A) Acetic acid and malonic acid are converted to their coenzyme A (CoA) esters and 
then attached, by speciﬁ  c acyl transferases, to components of the polyketide synthase 
(PKS): acetyl-CoA is attached to the active site of the ketosynthase, and malonyl-CoA to 
a structural component of the PKS called the acyl carrier protein (ACP). Condensation 
of the two units by the ketosynthase, with loss of one carbon from malonyl-CoA as carbon 
dioxide, produces a four-carbon chain attached to the ACP. This is transferred back to 
the ketosynthase, and further rounds of condensation with malonyl-CoA (as shown) or 
other chain extender units produce a polyketide chain. 
(B) The three-step reductive cycle that converts a keto group to a hydroxyl, then to a 
double bond, and ﬁ  nally to a fully saturated carbon. 
(C) A complex polyketide in which keto groups, hydroxyl groups, double bonds, and 
fully saturated carbons occur at different positions along the chain, depending on the 
operation of the reductive cycle after each condensation.February 2004  |  Volume 2  |  Issue 2  |  Page 0168 PLoS Biology  |  http://biology.plosjournals.org
groups (–OH), formed by reduction 
of a keto group, at others; double 
bonds between some adjacent carbon 
atoms, resulting from removal of the 
hydroxyl by loss of water (dehydration); 
or full saturation with hydrogen 
atoms elsewhere, arising by ‘enoyl’ 
reduction of the double bond (Figure 
1C). A further variable concerns the 
stereochemistry of the hydroxyl groups 
and methyl or other carbon branches, 
each of which can exist in two possible 
conﬁ  gurations. Finally, the nascent 
carbon chain adopts different folding 
patterns after it leaves the PKS, and 
‘tailoring’ enzymes can then add sugars 
or other chemical groups to it at many 
alternative positions, enabled by the 
pattern of chemical reactivity built 
into the polyketide by the PKS. The 
challenge has been to understand the 
programming of the PKS that accounts 
for this gamut of structural variation.
During the 1990s, the ability to 
manipulate actinomycete genes, 
developed over previous decades, 
mainly using the model species 
Streptomyces coelicolor (Hopwood 
1999), was combined with chemical 
and biochemical experiments to 
begin to crack this ‘polyketide code’. 
The ﬁ  rst studies were on organisms 
making antibiotics of the ‘aromatic’ 
family, which includes tetracycline 
and doxorubicin, as well as the model 
compounds actinorhodin (made by 
S. coelicolor itself) and tetracenomycin. 
The main variable in their structure 
is carbon chain length, with few 
choices of different building units 
or keto group modiﬁ  cation, so the 
programming would (in principle) 
be simple. The DNA sequences 
responsible for such PKSs revealed sets 
of genes encoding proteins, including 
ketosynthases, ketoreductases, and 
acyl carrier proteins (ACPs) (the unit 
of the PKS on which the growing 
carbon chain is tethered; see Figure 
1A), that would come together to form 
a multicomponent PKS resembling 
a typical bacterial fatty acid synthase. 
In contrast, the DNA sequence of the 
gene set for the complex polyketide 
erythromycin, made by a relative of 
Streptomyces called Saccharopolyspora 
erythraea, which has more involved 
programming, revealed multifunctional 
proteins with the various enzymic 
functions carried out by active sites on 
the same polypeptide chain, as in a 
mammalian fatty acid synthase. 
The big surprise, though, was 
the ﬁ  nding of six sets, or modules, 
of such active sites, corresponding 
to the six rounds of condensation 
needed to build the carbon chain 
(Cortes et al. 1990; Donadio et al. 
1991). The modules each contain an 
acyl transferase (to load the extender 
unit onto the enzyme), as well as a 
ketosynthase and an ACP domain, 
together with exactly those reductive 
activities needed to generate the 
required pattern of modiﬁ  cation of the 
chain at each step of elongation. Thus 
was born an ‘assembly line’ model in 
which the program for the PKS is hard-
wired into the DNA and expressed in 
a linear array of active sites (domains) 
along the giant protein. This consists 
of the six chain-building modules, 
preceded by a short module for loading 
the starter unit and ending in a domain 
for releasing the completed carbon 
chain from the PKS. The carbon chain 
of the polyketide would be assembled 
and modiﬁ  ed progressively as the 
molecule moved along the protein, 
interacting with each domain in turn, 
which would select extender units, 
make carbon–carbon bonds, and 
modify keto groups as appropriate, 
depending on the presence or absence 
of domains for the three steps in the 
reductive cycle. 
The model arose from the gene 
sequence, but was rapidly tested by 
mutating individual domains or adding 
or deleting whole modules and by 
observing predicted changes in the 
polyketide product. Soon, dozens of 
engineered compounds had been 
made, and the ﬁ  eld mushroomed with 
the isolation of more and more clusters 
of genes for complex polyketides 
that both proved the generality of 
the model (with minor variations) 
and ﬁ  lled the need for spare parts 
for the engineering of countless new 
polyketides (Shen 2003). Several 
biotech companies were founded to 
exploit the potential for drug discovery.
Aromatic PKS Programming
Meanwhile, the programming of 
the aromatic PKSs was harder to 
understand. They had been found to 
contain only a single ketosynthase, 
which has to operate a speciﬁ  c 
number of times to build a carbon 
chain of the correct length, so how is 
this determined? How does a single 
reductive enzyme know which keto 
groups to modify? And how is the 
starter unit for building the carbon 
chain selected (the extender units are 
normally all malonyl-CoA, so no choice 
is involved)? Considerable progress 
had been made in constructing 
novel compounds by mixing and 
matching PKS subunits, but this was 
largely based on empirical knowledge 
about which components to put 
together (McDaniel et al. 1995). A 
speciﬁ  c subunit of the PKS, named 
the chain length factor (CLF), was 
deduced to have a major inﬂ  uence 
on carbon chain length (McDaniel et 
al. 1993), but this conclusion was not 
universally accepted in the absence of 
experimental evidence on its mode 
of action. Two recent publications 
by the Khosla laboratory at Stanford 
University describe signiﬁ  cant advances 
in understanding aromatic PKS 
programming and promise to turn 
the spotlight back onto engineered 
members of this class of compounds as 
potential drug candidates by allowing 
rational manipulation of the two key 
variables: carbon chain length and 
choice of starter unit.
In the ﬁ  rst paper (Tang et al. 2003), 
the authors explore the hypothesis that 
the CLF exerts control over carbon 
chain length by associating closely 
with the ketosynthase, a protein with 
which it shares considerable amino 
acid sequence similarity, giving rise 
to a channel of a certain size at the 
interface between the two proteins. By 
systematically changing amino acids at 
four key positions in the CLF, the size 
of the channel was altered. Thus, large 
amino acid residues in the CLF of a 
PKS that makes a 16-carbon chain were 
replaced by less bulky residues found 
in one that builds a 20-carbon chain, 
and the chain length of the product 
increased as expected. The authors 
propose that the length of the channel 
is the main factor in controlling the 
number of chain-extension steps 
that can take place to ﬁ  ll it. While 
protein–protein interactions with other 
PKS subunits may modulate this chain 
length control, the work represents 
a major step in understanding and 
manipulating the chain length of 
aromatic polyketides. 
What about the choice of starter 
unit? Most aromatic polyketides start 
with acetyl-CoA. An important earlier 
publication by Leadlay and colleagues 
(Bisang et al. 1999) had shown that this February 2004  |  Volume 2  |  Issue 2  |  Page 0169 PLoS Biology  |  http://biology.plosjournals.org
 
is not loaded directly onto the PKS, as 
had been assumed, but is derived by 
loss of carbon dioxide from a molecule 
of malonyl-CoA previously loaded 
onto the enzyme. This decarboxylation 
is catalysed by the CLF as an activity 
independent of its role in inﬂ  uencing 
carbon chain length. There are, 
however, certain aromatic polyketides, 
including the anticancer drug 
doxorubicin, an antiparasitic agent 
called frenolicin, and the estrogen 
receptor agonist R1128, that have 
different starters. 
What Tang et al. (2004) have 
deduced, as described in this issue of 
PloS Biology, is that the PKSs for these 
compounds consist of two modules 
of active sites. The components of 
each module are not activities carried 
on the same protein, as in the PKSs 
for the complex polyketides, but 
are all separate proteins. They form 
functional modules nevertheless. The 
newly recognized modules in the 
producers of compounds that start with 
nonacetate units have a dedicated ACP 
and a special ketosynthase that carries 
out a ﬁ  rst condensation, joining the 
unusual starter unit to the ﬁ  rst malonyl-
CoA extender unit. The starter module 
then hands the resulting ‘diketide’ on 
to the second module (ﬁ  rst reducing it, 
if appropriate, using reductive enzymes 
‘borrowed’ from fatty acid biosynthesis) 
for typical extension by successive 
condensation with malonyl-CoA units 
to complete the chain. If the starter 
module is not present, the second 
module defaults to its typical habit of 
decarboxylating malonyl-CoA to acetyl-
CoA and starts the chain with that. 
The excitement of the work for 
biotechnology is that it offers the 
prospect of engineering promising 
drug candidates by making novel 
combinations of starter and extender 
modules and perhaps of feeding the 
starter modules with a whole range of 
unnatural substrates (Kalaitzis et al. 
2003). It is encouraging that already, in 
the proof-of-principle studies reported 
by Tang et al. (2004), some products 
with improved in vitro antitumor 
activity were obtained.  
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